UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 255

Sortiert nach

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Majallat Jāmiʻat al-Malik ʻAbd al-ʻAzīz. Iqtiṣād wa-al-idārah, 2021-04, Vol.35 (2), p.1-24

Haifa Ali Al Ahmari, Haifa Ali Al Ahmari

2021

Link zum Volltext

Verfügbarkeit prüfen

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Majallat Jāmiʻat al-Malik ʻAbd al-ʻAzīz. Iqtiṣād wa-al-idārah, 2021-04, Vol.35 (2), p.1-24

Haifa Ali Al Ahmari, Haifa Ali Al Ahmari

2021

Link zum Volltext

Verfügbarkeit prüfen

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

Cancer medicine (Malden, MA), 2023-09, Vol.12 (17), p.18235-18245

2023

Link zum Volltext

Verfügbarkeit prüfen

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

HemaSphere, 2023-08, Vol.7 (S3), p.e85817f0-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology

Journal of patient-reported outcomes, 2022-07, Vol.6 (1), p.77-77, Article 77

2022

Link zum Volltext

Verfügbarkeit prüfen

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

HemaSphere, 2023-08, Vol.7 (S3), p.e602412a-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

HemaSphere, 2023-08, Vol.7 (S3), p.e451088e-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

HemaSphere, 2023-08, Vol.7 (S3), p.e20101d8

2023

Link zum Volltext

Verfügbarkeit prüfen

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

Leukemia, 2018-09, Vol.32 (9), p.2085-2087

2018

Link zum Volltext

Verfügbarkeit prüfen

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Cancers, 2023-05, Vol.15 (10), p.2859

2023

Link zum Volltext

Verfügbarkeit prüfen

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

BMC cancer, 2017-12, Vol.17 (1), p.852-852, Article 852

2017

Link zum Volltext

Verfügbarkeit prüfen

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

Frontiers in oncology, 2023-01, Vol.12, p.1056786-1056786

2023

Link zum Volltext

Verfügbarkeit prüfen

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Experimental hematology & oncology, 2015-09, Vol.4 (1), p.26-26, Article 26

2015

Link zum Volltext

Verfügbarkeit prüfen

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34 + Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

Cancers, 2021-01, Vol.13 (2), p.186

2021

Link zum Volltext

Verfügbarkeit prüfen

Erratum zu: Patient-Reported Outcomes in klinischer Praxis

Best practice onkologie, 2023-02, Vol.18 (1-2), p.59-60

2023

Link zum Volltext

Verfügbarkeit prüfen

Patient-Reported Outcomes in klinischer Praxis

Best practice onkologie, 2022-12, Vol.17 (12), p.636-646

2022

Link zum Volltext

Verfügbarkeit prüfen

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

HemaSphere, 2023-08, Vol.7 (S3), p.e551265b

2023

Link zum Volltext

Verfügbarkeit prüfen

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.7068-7068

2023

Link zum Volltext

Verfügbarkeit prüfen

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S404-S404

2023

Link zum Volltext

Verfügbarkeit prüfen

POSTER: MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S194-S194

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 255

Suche als RSS-Feed

Aktive Filter

ThemaHumans

ThemaInfections

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(251)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Disclosure of social responsibility information in the annual reports of GCC commercial banks: An empirical study

Correction to: Allogeneic hematopoietic stem cell transplantation improves long‑term outcome for relapsed AML patients across all ages: results from two East German Study Group Hematology and Oncology (OSHO) trials

Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low‐, intermediate‐1‐, intermediate‐2‐, and high‐risk myelofibrosis in JUMP, a Phase 3b, expanded‐access study

Physical exercise recommendations for patients with polycythemia vera based on preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97)

PB2185: EFFECT OF NEW OR WORSENING ANEMIA ON CLINICAL OUTCOMES IN PATIENTS WITH MYELOFIBROSIS (MF) TREATED WITH RUXOLITINIB (RUX): A POST HOC ANALYSIS OF THE COMFORT‐I AND ‐II TRIALS

An implementation study of electronic assessment of patient-reported outcomes in inpatient radiation oncology

Kidney Dysfunction Is Associated with Thrombosis and Disease Severity in Myeloproliferative Neoplasms: Implications from the German Study Group for MPN Bioregistry

P994: GERMLINE SINGLE‐NUCLEOTIDE VARIANTS (SNV) IN THE JAK‐STAT PATHWAY GENOME OF ADOLESCENT AND YOUNG ADULTS (AYA) AND NON‐AYA PATIENTS WITH BCR::ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (MPN)

PB1887: STING AGONIST FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH‐RISK MYELODYSPLASTIC SYNDROME: A FIRST‐IN‐CLINIC PHASE 1 STUDY OF GSK3745417

S213: BMS‐986158, A POTENT BET INHIBITOR, AS MONOTHERAPY AND IN COMBINATION WITH RUXOLITINIB OR FEDRATINIB IN INTERMEDIATE‐ OR HIGH‐RISK MYELOFIBROSIS (MF): RESULTS FROM A PHASE 1/2 STUDY

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS

Questions arising on phlebotomy in polycythemia vera: prophylactic measures to reduce thromboembolic events require patient-focused decisions

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

Anxieties, age and motivation influence physical activity in patients with myeloproliferative neoplasms - a multicenter survey from the East German study group for hematology and oncology (OSHO #97)

The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis

Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34 + Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia

Erratum zu: Patient-Reported Outcomes in klinischer Praxis

Patient-Reported Outcomes in klinischer Praxis

P719: RANDOMIZED PHASE 1-2 STUDY TO ASSESS SAFETY AND EFFICACY OF LOW-DOSE (LD) ORAL DECITABINE/CEDAZURIDINE (ASTX727) IN LOWER-RISK MYELODYSPLASTIC SYNDROMES (LR-MDS) PATIENTS: INTERIM SAFETY ANALYSIS

Consistency of pacritinib for spleen and symptom reduction in patients with myelofibrosis regardless of cytopenias

MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

POSTER: MPN-571 Effect of New or Worsening Anemia on Clinical Outcomes in Patients With Myelofibrosis (MF) Treated With Ruxolitinib (RUX): A Post Hoc Analysis of the COMFORT-I and -II Trials

Aktive Filter

Suchergebnisse filtern